Alto Neuroscience’s recent acquisition of ALTO-207, described as an ‘intriguing asset’ by William Blair, has garnered attention for its impressive efficacy in the PAX-D study. While pramipexole showed promise, concerns about functional unblinding in the study have been raised, potentially impacting the perceived efficacy. This move highlights the company’s commitment to expanding its portfolio in the field of neuroscience, particularly in the treatment of depression. With a focus on innovative solutions, Alto Neuroscience aims to address unmet medical needs and advance the understanding of mental health disorders.
Read more from benzinga.com
